A MD-2:TLR4 complex agonist compound is disclosed whose structure corresponds to Formula (I), as defined within. Also disclosed are a method of its preparation and use, as well as a pharmaceutical composition containing the same.Linvention concerne un composé agoniste du complexe MD-2:TLR4 dont la structure correspond à la formule (I) telle que définie. Linvention concerne également son procédé de préparation et dutilisation ainsi quune composition pharmaceutique contenant le composé.